(Q38185990)

30 August 2017

title

Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden (English)

1 reference

30 August 2017

0 references

Tracy L Skaer

1

1 reference

30 August 2017

publication date

1 May 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

32

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

457-466

1 reference

The prevalence and characteristics of fibromyalgia in the general population.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Hinders for continued work among persons with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Societal and patient burden of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Characteristics and healthcare costs of patients with fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Chronic opioid use in fibromyalgia syndrome: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

A framework for fibromyalgia management for primary care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Pharmacotherapy for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Pharmacological treatment of fibromyalgia syndrome: new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Women with fibromyalgia: work and rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Prevalence of widespread pain and associations with work status: a population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

An internet survey of 2,596 people with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Economic and humanistic burden of fibromyalgia in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Increased absence due to sickness among employees with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Disability and quality of life in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Characteristics of patients with fibromyalgia in France and Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Quality of life assessments with SF 36 in different musculoskeletal diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Assessment of anxiety and quality of life in fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Health economic consequences related to the diagnosis of fibromyalgia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Effect of fibromyalgia syndrome on the health-related quality of life and economic burden in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Cost-effectiveness of Spa treatment for fibromyalgia: general health improvement is not for free

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0137-Y

Optimizing fibromyalgia management

21 January 2018

1 reference

12 December 2020

Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain.

1 reference

12 December 2020

Health services costs and their determinants in women with fibromyalgia

1 reference

12 December 2020

Factors of importance for work disability in women with fibromyalgia.

1 reference

12 December 2020

Understanding fibromyalgia and its resultant disability

1 reference

12 December 2020

Hospitalisation charges for fibromyalgia in the United States, 1999-2007.

1 reference

12 December 2020

Prospective study of the use of healthcare resources and economic costs in patients with fibromyalgia after treatment in routine medical practice

1 reference

12 December 2020

Financial, occupational, and personal consequences of disability in patients with chronic fatigue syndrome and fibromyalgia compared to other fatiguing conditions.

1 reference

12 December 2020

Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently

1 reference

12 December 2020

Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico.

1 reference

12 December 2020

The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis

1 reference

12 December 2020

A meta-analysis of pain response in the treatment of fibromyalgia

1 reference

12 December 2020

Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy

1 reference

12 December 2020

A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia

1 reference

12 December 2020

Work disability and health system utilization in patients with fibromyalgia syndrome

1 reference

12 December 2020

Economic cost and epidemiological characteristics of patients with fibromyalgia claims.

1 reference

12 December 2020

Comorbidity of fibromyalgia and psychiatric disorders

1 reference

12 December 2020

10.1007/S40273-014-0137-Y

Identifiers

DOI

1 reference

release_6dxa2uwb4jbtjf3x35wtvptzti

30 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6dxa2uwb4jbtjf3x35wtvptzti

24 November 2022

mapped directly with Wikidata item

1 reference